Clinical trial
Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity
NCT03811574 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 21, 2019
- Completion date
- November 20, 2020
- Enrollment
- 401 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.